Table 2. Phase III trials MONET1 (10,11) and Kubota et al. study (12) to evaluate efficacy of motesanib.
| Variable | MONET 1 (stage IIIB/IV) | Kubota et al. study (stage IV) | |||||
|---|---|---|---|---|---|---|---|
| PCM | PC | P value | PCM | PC | P value | ||
| Number of patients (N) | 541 | 549 | – | 197 | 204 | – | |
| Median PFS (month) | 5.6 | 5.4 | <0.05 | 6.1 | 5.6 | NS | |
| ORR (%) | 40 | 26 | <0.05 | 60.1 | 41.6 | <0.05 | |
| Median OS (month) | 13 | 11 | NS | Not reached | 21.6 | NS | |
PCM, paclitaxel-carboplatin-motesanib; PC, paclitaxel-carboplatin-placebo; PFS, progression free survival; ORR, objective response rate; OS, overall survival; NS, not significant (P>0.05).